Article
Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
BMC cancer - 24 Feb 2020
Adachi Yuta, Yanagimura Naohiro, Suzuki Chiaki, Ootani Sakiko, Tanimoto Azusa, Nishiyama Akihiro, Yamashita Kaname, Ohtsubo Koushiro, Takeuchi Shinji, Yano Seiji
Abstract excerpt
BACKGROUND: A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combination therapy has not yet been reported. CASE PRESENTATION: A Japanese man in his mid-sixties was diagnosed with unresectable lung adenocarcinoma and was unresponsive to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.